Investigation into an FDA device program; top cancer hospitals slap hefty markups on drugs

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Animal rights group urges USDA to probe research facilities for failing to inspect monkey shipments By Ed Silverman JEAN-FRANCOIS MONIER/AFP/Getty Images PTA cited documents that indicated timely inspections did not take place before or after the monkeys were shipped across state lines. Read More STAT+: Nation's top cancer hospitals slap hefty markups on drugs, study says By Bob Herman BRENDAN SMIALOWSKI/AFP/GettyImages A new study finds health insurers paid drastically different prices for common cancer therapies at top cancer hospitals. Read More As FDA offers breakthrough designation to device makers, patients and providers are left with questions By Katie Palmer and Mario Aguilar Jacquelyn Martin/AP The FDA's breakthrough device program aims to get new tech to patients faster. But the agency's decision-making process remains secretive. Read More Sponsor content by RARE ACCESS ACTION PROJECT Rare disease patients deserve protection from Washington politics Right now, politicians need a win, but rare disease patients could lose. In Congress' rush to pass something, therapies for rare diseases and cancers could face an increase of between 400% and 800% in Medicare Part D costs. There is a better way that protects patients. Learn more. STAT+: Breakthrough Device Tracker: An authoritative database of FDA's fast-tracked medical devices By Katie Palmer and Mario Aguilar and J. Emory Parker STAT identified hundreds of medical devices designated as "breakthroughs" by the FDA. Explore them by indication, manufacturer, and more. Read More Monday, April 18, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser